Krinzinger, H;
L Hall, C;
Groom, MJ;
T Ansari, M;
Banaschewski, T;
Buitelaar, JK;
Carucci, S;
... Liddle, EB; + view all
(2019)
Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence.
Neuroscience & Biobehavioral Reviews
, 107
pp. 945-968.
10.1016/j.neubiorev.2019.09.023.
Preview |
Text
Wong_1-s2.0-S0149763419302350-main.pdf - Published Version Download (1MB) | Preview |
Abstract
Methylphenidate (MPH), the most common medication for children with Attention Deficit/Hyperactivity Disorder (ADHD) in many countries, is often prescribed for long periods of time. Any long-term psychotropic treatment in childhood raises concerns about possible adverse neurological and psychiatric outcomes. // We aimed to map current evidence regarding neurological and psychiatric outcomes, adverse or beneficial, of long-term MPH (> 1 year) treatment in ADHD. We coded studies using a “traffic light” system: Green: safe/favours MPH; Amber: warrants caution; Red: not safe/not well-tolerated. Un-categorisable study findings were coded as “Unclear”. // Although some evidence suggests an elevated risk of psychosis and tics, case reports describe remission on discontinuation. Several studies suggest that long-term MPH may reduce depression and suicide in ADHD. Evidence suggests caution in specific groups including pre-school children, those with tics, and adolescents at risk for substance misuse. // We identified a need for more studies that make use of large longitudinal databases, focus on specific neuropsychiatric outcomes, and compare outcomes from long-term MPH treatment with outcomes following shorter or no pharmacological intervention.
| Type: | Article |
|---|---|
| Title: | Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: A map of the current evidence |
| Open access status: | An open access version is available from UCL Discovery |
| DOI: | 10.1016/j.neubiorev.2019.09.023 |
| Publisher version: | https://doi.org/10.1016/j.neubiorev.2019.09.023 |
| Language: | English |
| Additional information: | Copyright © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/). |
| Keywords: | Long-term methylphenidate treatment; ADHD; adverse neuropsychiatric events; mood; anxiety; suicidal ideation; bipolar; psychosis; substance use disorder; tics; seizures; sleep disorders |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Life Sciences > UCL School of Pharmacy > Practice and Policy |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10083423 |
Archive Staff Only
 |
View Item |
